Daily Sepsis Research Analysis
Three impactful sepsis studies span prevention, implementation science, and mechanism: (1) translational work defines cross-reactive K- and O-antigen targets to guide Klebsiella pneumoniae neonatal sepsis vaccines; (2) a multicenter stepped-wedge cluster RCT found machine-learning clinical decision support did not improve early treatment of pediatric septic shock; and (3) mechanistic data reveal an EZH1–NRF2 epigenetic-ferroptosis axis in sepsis-associated liver injury with a druggable target.
Summary
Three impactful sepsis studies span prevention, implementation science, and mechanism: (1) translational work defines cross-reactive K- and O-antigen targets to guide Klebsiella pneumoniae neonatal sepsis vaccines; (2) a multicenter stepped-wedge cluster RCT found machine-learning clinical decision support did not improve early treatment of pediatric septic shock; and (3) mechanistic data reveal an EZH1–NRF2 epigenetic-ferroptosis axis in sepsis-associated liver injury with a druggable target.
Research Themes
- Neonatal sepsis vaccine antigen selection (Klebsiella pneumoniae)
- Machine-learning clinical decision support in pediatric septic shock
- Epigenetic control of ferroptosis in sepsis-associated liver injury
Selected Articles
1. The characterization of Klebsiella pneumoniae associated with neonatal sepsis in low- and middle-income countries to inform vaccine design.
Using LMIC neonatal sepsis isolates, the study integrates genomics, structural polysaccharide analysis, and functional assays to show that both K- and O-antigen–targeting antibodies bind broadly and can mediate bactericidal activity. Cross-reactivity and lack of correlation between polysaccharide features and susceptibility support feasible vaccine compositions against Klebsiella pneumoniae.
Impact: Defines antigen candidates and cross-reactive breadth critical for rational Klebsiella neonatal sepsis vaccine design, addressing a major AMR-linked cause of mortality.
Clinical Implications: Supports inclusion strategies for K- and/or O-antigen components in vaccine formulations and prioritizes antigens with broad cross-reactivity to maximize coverage of neonatal Klebsiella sepsis.
Key Findings
- Antibodies against common K- and O-antigens bound all homologous isolates regardless of polysaccharide structural features.
- Anti-K-antigen antibodies showed bactericidal activity against a comparable number of isolates as anti-O-antigen antibodies.
- No association was found between polysaccharide characteristics and susceptibility of K. pneumoniae to killing.
- Cross-reactivity was observed among different K-antigens and extensively among O-antigen antibodies.
- Findings inform optimal vaccine composition to prevent neonatal sepsis caused by K. pneumoniae.
Methodological Strengths
- Integrated genomic prediction with structural polysaccharide validation.
- Functional bactericidal assays across clinically relevant LMIC isolates.
Limitations
- Preclinical in vitro and ex vivo analyses without clinical efficacy data.
- Sample size and geographic breadth beyond BARNARDS sites not detailed.
Future Directions: Evaluate in vivo protective efficacy and breadth across global strain collections; optimize multivalent K/O-antigen combinations; advance to GMP antigen production and early-phase clinical trials.
Klebsiella pneumoniae is the leading cause of neonatal sepsis, strongly associated to antimicrobial resistance, with no vaccine available. K-antigens (KAg) have been identified as potential targets, but their diversity makes vaccine development challenging. Alternatively, the use of subcapsular O-antigens (OAg) raises questions about antibodies accessibility. We characterized clinical isolates from the BARNARDS study, designed to identify the burden of neonatal sepsis in low-middle income countries. Genomic prediction was verified through structural analysis of polysaccharides. Antibodies generated against common KAg and OAg bound all homologous organisms, regardless of specific polysaccharide structural features. Interestingly, anti-KAg antibodies exhibited bactericidal activity against a comparable number of isolates as anti-OAg antibodies. There was no association between polysaccharide characteristics and K. pneumoniae susceptibility to killing. Antibody cross-reactivity among different KAg was observed, together with extensive cross-reactivity among OAg antibodies. This study aids in defining an optimal vaccine composition to prevent neonatal sepsis caused by K. pneumoniae.
2. Clinical Decision Support for Septic Shock in the Emergency Department: A Cluster Randomized Trial.
In a multicenter stepped-wedge cluster RCT across four pediatric EDs (n=1331), a machine-learning–based CDS did not increase early sepsis treatment within 1 hour or reduce progression to hypotensive shock, despite being feasible and acceptable to providers. This high-quality negative result informs real-world CDS deployment strategies.
Impact: Provides rigorous randomized evidence that predictive CDS, as implemented with infrequent alerts, did not improve early septic shock care processes in pediatrics, guiding future CDS design and policy.
Clinical Implications: CDS tools should be iteratively optimized (e.g., alert thresholds, workflow integration, frequency) and prospectively evaluated; clinicians should not assume benefit from low-frequency predictive alerts without outcome data.
Key Findings
- Primary outcome (antibiotics plus bolus within 1 hour) was similar between intervention and control arms (39.0% vs 38.9%; aOR 1.07, 95% CI 0.61–1.88).
- No differences in progression to hypotensive septic shock or time-to-antibiotics (aHR 0.85, 95% CI 0.63–1.16).
- CDS was feasible, acceptable, and maintained post-trial despite lack of measured clinical benefit.
Methodological Strengths
- Prospective stepped-wedge cluster randomized design across multiple EDs.
- Predefined primary/secondary outcomes with adjusted analyses and qualitative implementation evaluation.
Limitations
- Low alert frequency may limit intervention intensity and effect size.
- Generalisability constrained to pediatric ED settings and specific CDS configuration.
Future Directions: Test higher-sensitivity or tiered alert strategies, closed-loop order sets, and clinician-in-the-loop designs; evaluate CDS in broader settings and with adaptive thresholds linked to outcomes.
BACKGROUND AND OBJECTIVES: Delays in septic shock diagnosis cause preventable mortality in children. Evidence is limited around early recognition strategies. The hypothesis was that clinical decision support (CDS) based on machine-learning predictive models would increase the proportion of children receiving septic shock treatment prior to shock onset. METHODS: CDS was implemented in a prospective, stepped-wedge, cluster randomized trial in 4 pediatric emergency departments (EDs) over five 10-week periods. The CDS used models identifying children who did not yet have shock but were predicted to be at high risk based on electronic health record data at arrival and after 2 hours. Providers received CDS; effectiveness was evaluated in patients 60 days to 18 years with concern for sepsis. The primary outcome was antibiotic and bolus within 1 hour of sepsis suspicion. Secondary outcomes were time-to-antibiotic, hypotensive septic shock. Implementation outcomes were evaluated in qualitative interviews. RESULTS: Of 200 354 ED encounters from March 16, 2022, to March 1, 2023, 1331 encounters met inclusion criteria (979 intervention, 352 control arms). Antibiotic and bolus within 1 hour occurred in 39.0% of patients in the intervention arm versus 38.9% of patients in the control arm (adjusted odds ratio [aOR]: 1.07 [0.61-1.88]). There was no difference in outcomes of shock (aOR: 1.12 [0.53-2.46]) or antibiotic timeliness (aHR: 0.85 [0.63-1.16]). Providers reported the CDS felt valuable and unobtrusive (adoption); 6 months after the trial, EDs continued to use the CDS (maintenance). CONCLUSIONS: Implementing predictive CDS that infrequently alerted was feasible and acceptable. It did not change the proportion of patients with suspected sepsis who progressed to hypotensive shock.
3. EZH1 deficiency promotes ferroptosis resistance by activating NRF2 in sepsis-associated liver injury.
In murine lethal sepsis and in vitro LPS models, EZH1 deficiency reduces H3K27me3 at the Nfe2l2 promoter, increases NRF2 expression and nuclear translocation, suppresses hepatocellular ferroptosis, and improves survival. Pharmacologic EZH1 inhibition (DS3201) confers anti-ferroptosis effects reversible by the NRF2 inhibitor ML385, highlighting a druggable epigenetic-ferroptosis axis in SALI.
Impact: Reveals an epigenetic mechanism (EZH1–H3K27me3) controlling NRF2-driven ferroptosis resistance in SALI with survival benefit, nominating EZH1 inhibition as a therapeutic strategy.
Clinical Implications: Suggests testing EZH1 inhibitors as adjunctive therapy in sepsis-associated liver injury; potential biomarker development around H3K27me3/NRF2 activity to guide patient selection and dosing.
Key Findings
- EZH1 deficiency improved survival in a murine lethal sepsis model and alleviated sepsis-associated acute liver injury.
- Reduced H3K27me3 at the Nfe2l2 promoter increased NRF2 expression and nuclear translocation, suppressing hepatocellular ferroptosis.
- The EZH1 inhibitor DS3201 exhibited anti-ferroptosis effects in LPS-induced models, which were reversed by the NRF2 inhibitor ML385.
Methodological Strengths
- Convergent in vivo survival and mechanistic promoter/epigenetic assays.
- Pharmacologic validation with both activator pathway and inhibitor reversal.
Limitations
- Preclinical animal and cell models without human translational data.
- Potential off-target effects of EZH1 inhibition and need for safety profiling in sepsis.
Future Directions: Validate EZH1–NRF2–ferroptosis biomarkers in human SALI; test EZH1 inhibitors in large-animal sepsis models; delineate cell-type specificity and therapeutic window.
Sepsis-associated acute liver injury (SALI) is a major clinical complication of sepsis due to excessive, unfettered inflammation. In recent years, the role of epigenetic regulatory mechanisms in SALI has been gradually emphasized. Here, we investigated the effects of a Histone-lysine N-methyltransferase EZH1 (Enhancer of zeste homolog 1) inhibition on promoting ferroptosis resistance to activate nuclear factor, erythroid derived 2, like 2 (NRF2) in SALI. We found that EZH1 deficiency improved animal survival in lethal sepsis. EZH1 deficiency mice exhibited alleviated SALI with decreased hepatocellular ferroptosis. EZH1 deficiency attenuated the H3K27me3 modification in the Nfe2l2 promoter, lending to the increased expression and nuclear translocation of NRF2. In the in vitro, LPS-induced ferroptosis model, EZH1 inhibitor DS3201 exhibited an anti-ferroptosis effect, which was reversed NRF2 inhibitor ML385. These findings indicate that EZH1 deficiency or inhibition with DS3201 alleviates ferroptosis in the liver by activating the NRF2, and it is suggested that targeting EZH1 may be a new therapeutic strategy in SALI.